S&CO Inc. Sells 4,323 Shares of Royalty Pharma plc (NASDAQ:RPRX)

S&CO Inc. decreased its position in Royalty Pharma plc (NASDAQ:RPRX) by 1.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 358,162 shares of the biopharmaceutical company’s stock after selling 4,323 shares during the period. S&CO Inc. owned about 0.06% of Royalty Pharma worth $9,136,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in RPRX. Swedbank AB lifted its stake in Royalty Pharma by 2.0% in the third quarter. Swedbank AB now owns 11,027,370 shares of the biopharmaceutical company’s stock worth $311,964,000 after acquiring an additional 213,900 shares during the period. Van ECK Associates Corp lifted its stake in Royalty Pharma by 171.1% in the third quarter. Van ECK Associates Corp now owns 101,500 shares of the biopharmaceutical company’s stock worth $2,777,000 after acquiring an additional 64,057 shares during the period. Sumitomo Mitsui Trust Group Inc. lifted its stake in Royalty Pharma by 1.6% in the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,009,541 shares of the biopharmaceutical company’s stock worth $28,560,000 after acquiring an additional 15,963 shares during the period. New South Capital Management Inc. lifted its stake in Royalty Pharma by 5.0% in the third quarter. New South Capital Management Inc. now owns 2,466,371 shares of the biopharmaceutical company’s stock worth $69,774,000 after acquiring an additional 117,394 shares during the period. Finally, Victory Capital Management Inc. lifted its stake in Royalty Pharma by 26.8% in the third quarter. Victory Capital Management Inc. now owns 849,035 shares of the biopharmaceutical company’s stock worth $24,019,000 after acquiring an additional 179,411 shares during the period. Hedge funds and other institutional investors own 54.35% of the company’s stock.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $32.75 on Tuesday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $18.88 billion, a P/E ratio of 22.59, a P/E/G ratio of 2.31 and a beta of 0.47. The business has a fifty day simple moving average of $31.02 and a two-hundred day simple moving average of $28.44. Royalty Pharma plc has a 12 month low of $24.05 and a 12 month high of $34.20.

Royalty Pharma (NASDAQ:RPRX) last announced its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a return on equity of 24.40% and a net margin of 37.94%. On average, equities analysts forecast that Royalty Pharma plc will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, March 10th. Stockholders of record on Friday, February 21st were issued a dividend of $0.22 per share. The ex-dividend date was Friday, February 21st. This is an increase from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 annualized dividend and a dividend yield of 2.69%. Royalty Pharma’s dividend payout ratio (DPR) is presently 60.69%.

Analyst Ratings Changes

Separately, TD Cowen raised Royalty Pharma to a “strong-buy” rating in a research report on Tuesday, December 24th. One investment analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $41.60.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.